Yazar "Ozgen, A. Gokhan" seçeneğine göre listele
Listeleniyor 1 - 6 / 6
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe 33 Questions about Triglycerides and Cardiovascular Effects: Expert Answers(Turkish Soc Cardiology, 2017) Cetinkalp, Sevki; Koylan, Nevrez; Ozer, Necla; Onat, Altan; Ozgen, A. Gokhan; Koldas, Z. Lale; Guven, Gulay Sain; Ozdogan, Oner; Karsidag, Kubilay; Yigit, Zerrin; Kayikcioglu, Meral; Tokgozoglu, Lale; Can, Levent H.; Tartan, Zeynep; Kultursay, Hakan; Karpuz, Baris; Kirilmaz, Bahadir; Ersanli, Murat; Ural, Dilek; Erbakan, Ayse Naciye; Oguz, Aytekin; Kayikcioglu, Ozcan R.; Temizhan, Ahmet; Sansoy, Vedat; Ceyhan, Ceyhun; Ongen, Zeki; Bayram, Fahri; Orem, Cihan; Sonmez, Alper; Beyaz, Sengul; Ukinc, Kubilay; Yurekli, Banu Sarer; Coker, Mahmut; Canda, Ebru; Simsir, Ilgin YildirimÖğe Apolipoprotein E gene polymorphism and polycystic ovary syndrome patients in Western Anatolia, Turkey(Springer/Plenum Publishers, 2009) Cetinkalp, Sevki; Karadeniz, Muammer; Erdogan, Mehmet; Zengi, Ayhan; Cetintas, Vildan; Tetik, Asli; Eroglu, Zuhal; Kosova, Buket; Ozgen, A. Gokhan; Saygili, Fusun; Yilmaz, CandegerDyslipidemia, cardiovascular disease and hypertension are more frequently seen in patients with PCOS than in normal patients. We aimed at evaluating the distribution of Apo E alleles that can influence cardiovascular risk of the PCOS patients and control subjects. In this study, 129 young women with PCOS and 91 healthy women were included. In all subjects we performed hormonal, biochemical and Apo E genetic analysis. The Apo E3 allele was found at a significantly higher frequency in the PCOS patient group compared with the control group. The Apo E2 allele was found at a significantly higher frequency in the control group compared with the patient group with PCOS. Although there were genotype and allele differences between control and patient groups in this study, no statistically significant change was determined in lipid and other cardiovascular risk factors in connection with allele and genotype.Öğe Demographic and clinical features of patients with subacute thyroiditis: Results of 169 patients from a single University Center in Turkey(Springer, 2007) Erdem, N.; Erdogan, M.; Ozbek, M.; Karadeniz, M.; Cetinkalp, S.; Ozgen, A. Gokhan; Saygili, F.; Yilmaz, C.; Tuzun, M.; Kabalak, T.Background: Turkey is an endemic area for thyroid diseases. The Aegean region is well documented for increased prevalence of thyroid disorders. In this study we investigated the demographic and clinical features of subacute thyroiditis (SAT) patients who had been diagnosed and treated in Ege University. Methods: The hospital files of patients admitted to the endocrinology clinic of Ege University between January 1987 and December 2001 were retrospectively evaluated. Patients who had been diagnosed as having any thyroid disorder were determined. Results: 176 fulfilled diagnostic criteria for SAT. The majority of patients with SAT were diagnosed as having subacute granulomatous thyroiditis (169/176) (134 females, 35 males, mean age 34.0 +/- 17.8 yr); 69% of the patients were between 30-50 yr of age. Thyroid pain was present in 97.1% of female patients, and in 100% of male patients. High fever was evident in 78 patients (46.2%). Mean erythrocyte sedimentation rate (ESR) was 43-42 +/- 39.68 mm/h. Anti-thyroglobulin antibody was positive in 20%, and anti-thyroid per-oxydase antibody was positive in 4% of patients. Among patients who were treated with non-steroidal anti-inflammatory drugs (NSAD) 10 female patients (10.6%), and 3 male patients (12%) developed recurrence of the disease. Among patients who were treated with prednisolone 7 female patients (17.5%), and one male patient (10%) developed recurrence. There was no significant difference regarding the recurrence rates between patients who were treated with NSAD and patients who were treated with prednisolone. Conclusion: With the exception of ESR, demographic, clinical, laboratory, and imaging findings and prognoses of our patients were comparable to the previous reports.Öğe Effects of bisphosphonates on lipid metabolism(Maghira & Maas Publications, 2008) Guney, Engin; Kisakol, Gurcan; Ozgen, A. Gokhan; Yilmaz, Candeger; Kabalak, TaylanOBJECTIVES: Bisphosphonates are widely used for the treatment of metabolic bone disorders and their effects on lipid metabolism have also been investigated. Some studies reported that bisphosphonates have beneficial effects on serum cholesterol levels. In this study we aimed to assess the effects of bisphosphonates on lipid levels in hyperlipidemic patients who received bisphosphonates because of osteoporosis. METHODS: 49 female patients (age: 54.2 +/- 7.2 years) with diagnosis of osteoporosis and hyperlipidemia were enrolled. Patients received alendronate 10 mg/day and they were followed up for 6 months. Pretreatment total cholesterol, triglyceride, HDL-cholesterol, LDL-cholesterol, apolipoprotein A1 and apolipoprotein B levels were measured and compared with post-treatment levels. RESULTS: Pretreatment and post-treatment levels of total cholesterol were 255.2 +/- 34.3; 233.02 +/- 37.0 mg/dL, triglyceride levels were 153.0 +/- 57.3; 129.1 +/- 54.4 mg/dL, and LDL levels were 170.7 +/- 30.5; 160.0 +/- 34.2 mg/dL, respectively. Reductions in total cholesterol, triglyceride and LDL-cholesterol levels were statistically significant; whereas differences in HDL-cholesterol, apolipoprotein-A1 and apolipoprotein-B levels were not significant. CONCLUSIONS: Data from our study suggest that alendronate therapy may have beneficial effects on lipid metabolism. Thus, when hyperlipidemia is detected in patients receiving bisphosphonates, it is considered reasonable to follow the patient for a while before initiating antihyperlipidemic agent to prevent unnecessary use of drugs.Öğe Long-term treatment with acarbose for the treatment of reactive hypoglycemia(1998) Ozgen, A. Gokhan; Hamulu, F; Bayraktar, Fırat; Çetinkalp, Şevki; Yılmaz, Candeğer; Tüzün, Mehmet; Kabalak, T…Öğe Prolactin levels and examination with breast ultrasound or mammography(Springer, 2008) Sarac, Fulden; Tutuncuoglu, Pelin; Ozgen, A. Gokhan; Saygili, Fusun; Yilmaz, Candeger; Bilgen, Isil; Memis, AysenurObjective: Stresses including surgery, exercise, nipple stimulation, and chest wall injury such as mechanical trauma, burns, surgery, herpes zoster of thoracic dermatomes, hypoglycaemia and acute myocardial infarction cause significant elevation of prolactin levels. The aim of the present study was to evaluate the changes in prolactin level during mammography and ultrasonographic examination. Materials and Methods: Seventy-four premenopausal ( mean age, 32.1 +/- 7.3 y) and 81 post-menopausal women ( mean age, 48.3 +/- 8.9 y) were enrolled into the study. Premenopausal women were evaluated with ultrasound (Senographe 600 T [ General Electric]) and post-menopausal women were examined with mammography (Mammomat 3000 [ Siemens]). Blood samples for prolactin were taken prior to ultrasound or mammography and 15, 30 and 45 min after ultrasound or mammography. Results: Mean baseline serum prolactin level was 7.2 +/- 0.9 ng/ml in premenopausal women before ultrasound. Mean baseline serum prolactin level was 5.4 +/- 0.4 ng/ml in post-menopausal women before mammography. It was found that there were no significant changes in prolactin levels after ultrasound or mammography (P > 0.05). Mean levels of baseline prolactin were statistically significant higher in premenopausal than in post-menopausal women (P=0.03). Conclusion: Mammography and ultrasonographic examination have no acute effect on serum prolactin levels in either group. There is no need to wait before measuring the prolactin level after mammographic or ultrasonographic breast examination.
